Pulmatrix Inc. (PULM)

Trade PULM now with
8/8/2022 9:08:26 AM Pulmatrix, Inc. Q2 Net Loss/shr $1.36 Vs. Loss/shr $1.37 Last Year
7/12/2022 9:11:03 AM Pulmatrix Says First Subject Dosed In Phase 1 Study Of PUR3100 For Acute Migraine
3/29/2022 9:09:33 AM Pulmatrix FY Revenue $5.2 Mln Vs. $12.6 Mln Prior Year
3/21/2022 8:08:00 AM Pulmatrix Announces Positive Top-Line Data From Phase 1b Clinical Study Of PUR1800 In Patients With Stable COPD
11/9/2021 9:12:19 AM Pulmatrix Reports Resolution Of Contract Dispute With Cipla
8/10/2021 9:13:43 AM Pulmatrix Q2 Net Loss $3.9 Mln Vs Loss Of $1.2 Mln Last Year
4/12/2021 9:16:09 AM Pulmatrix To Regain Full Rights To Its Narrow Spectrum Kinase Inhibitor Portfolio
2/11/2021 12:33:24 AM Pulmatrix Announces $40 Mln Registered Direct Offering Priced At-the-Market Under Nasdaq Rules